Psychiatry Drug Alerts​​

In recent issues...​
​​  
  • Genomics and Antidepressant Outcomes
  • Psychiatric Adverse Effects of Oseltamivir
  • Clozapine Activity and Inflammation
  • Single-Dose IV Ketamine: Optimal Dosage
  • Repeated Oral Ketamine for Resistant Depression
  • Medical Marijuana in Psychiatr y
  • Biomarkers for Suicidal Ideation
  • SAGE-217 for Depression
  
  
 

Child & Adolescent Psychiatry Alerts

In recent issues...​
      
  • Lisdexamfetamine-Associated Raynaud’s Phenomenon
  • ADHD History and Neurologic Disorders
  • Gender Differences in Risk-Taking Behavior
  • Add-On rTMS for Adolescent Depression
  • Guided Internet CBT for Anxiety
  • Ecopipam for Tourette Syndrome
  
  
  





​​
MJ Powers & Co publishes monthly newsletters about the efficacy and safety of drugs and therapeutics. The Alerts contain summaries, from a wide variety of journals, that can help you solve a problem, warn you about safety, or reassure you about efficacy. Not only will you receive the latest research findings, but also useful tools to help you judge research quality, evaluate study independence, and guide you with statistics. 

The Alerts Newsletters are timely and thorough, and you can be assured of objectivity because MJ Powers & Co is independent. There is no sponsorship associated with any of our newsletters, and we accept no advertising. In addition, as a subscriber you will be eligible to enroll in our CME program, which your colleagues consistently rate as "excellent" and "practice changing". 
​​​​
FULL ISSUES ARE AVAILABLE TO SUBSCRIBERS
Login In
Subscribe
Psychiatry Alerts NOS​​​

In recent issues...​
 
  • Highly Concentrated Treatment of OCD
  • Traumatic Brain Injury and Suicide Risk
  • rTMS During Pregnancy
  • CBT with Heart Rate Variability Biofeedback for PTSD
  • Habenular Connectivity and Depression Response
  
  



​​Primary Care Drug Alerts​​​

In recent issues...​
       
  • Baloxavir Approved for Influenza Treatment
  • Psychiatric Effects of Oseltamivir
  • Expanded Gardasil Use
  • Galcanezumab for Migraine Prevention
  • Lisdexamfetamine: Raynaud’s Phenomenon
  • Perimenopausal Depression Guidelines
  • Lower-Dose EpiPen Alternative
  
  
    


​​